Lucinda Ignarro is a passionate researcher focused on investigating cutting-edge solutions in the field of metabolic health, particularly concerning diabetes and its broader impact on patient outcomes. As part of her work at the Baker Heart and Diabetes Institute, she is involved in research exploring the regeneration of pancreatic cells to offer innovative pathways for the treatment and potential cure of diabetes.

Under the supervision of Professor Sam El Osta and reputable epigenetics researchers at the Baker Institute, Lucinda collaborates on research leveraging molecular biology and epigenetic tools to better understand the mechanisms behind pancreatic regeneration. Their aim is to address the growing global burden of diabetes by exploring therapies that may ultimately lead to pancreatic regeneration, thereby restoring insulin function. The team's current research focuses on inhibiting the Enhancer Zeste Homolog 2 (EZH2) protein, guiding pancreatic ductal progenitors toward a beta-cell phenotype to enhance the expression of beta-cell markers. Their work integrates the latest advancements in genetic and cell-based technologies, positioning them at the forefront of epigenetic-based treatments.

Lucinda’s interest in this area stems from her passion for improving the quality of life for patients suffering from metabolic and chronic diseases. Through her work, she hopes to contribute to the development of novel therapeutic approaches, aspiring to influence both scientific understanding and future clinical practices in diabetes management.